ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,836.22
0.16%
US Tech 100
20,259.60
-0.14%
Dow Jones
42,297.12
0.86%
Brent Oil
80.205
-0.51%
Bitcoin
94,283.05
-0.22%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE

  6. Vivoryon Therapeutics Nv (0R3M) Quote

Vivoryon Therapeutics Nv

Vivoryon Therapeutics Nv (0R3M)

LSE
4.71
0.00
(0.00%)
Closed January 13 11:30AM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
4.71
Bid
0.00
Ask
0.00
Volume
2,296
0.00 Day's Range 0.00
4.71 52 Week Range 4.71
Market Cap
-
Previous Close
4.71
Open
-
Last Trade
240
@
1.96
(O)
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
4,467
Shares Outstanding
0.00
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-
Revenue
-3.62M
Net Profit
-28.34M

About Vivoryon Therapeutics Nv

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.vivoryon.com
Headquarters
Halle, Deu
Founded
-
Vivoryon Therapeutics Nv is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker 0R3M. The last closing price for Vivoryon Therapeutics Nv was 4.71 €. Over the last year, Vivoryon Therapeutics Nv shares have traded in a share price range of 4.71 € to 4.71 €.

Vivoryon Therapeutics Nv currently has 0 shares outstanding.

Ask ADVFN Intelligence (AI)

0R3M Latest News

More News

Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function

Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function Vivoryon Therapeutics N.V. Presents Topline Phase...

December 09 2024
UK Regulatory

Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024

Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024 Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress...

December 04 2024
UK Regulatory

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of...

October 26 2024
UK Regulatory

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 Halle (Saale) / Munich, Germany, October 11, 2024 – Vivoryon...

October 11 2024
UK Regulatory

Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event

Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event Halle (Saale) / Munich, Germany, October 1, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY;...

October 01 2024
UK Regulatory

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease Vivoryon Therapeutics N.V...

September 12 2024
UK Regulatory

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and...

September 05 2024
UK Regulatory

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024 Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial...

September 05 2024
UK Regulatory

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in...

July 18 2024
UK Regulatory

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on...

July 09 2024
UK Regulatory
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1004.714.714.716314.71DE
4004.714.714.7114524.71DE
12004.714.714.7144674.71DE
26004.714.714.7169104.71DE
52004.714.714.71123464.71DE
156004.714.714.7159834.71DE
260004.714.714.7142344.71DE

0R3M - Frequently Asked Questions (FAQ)

What is the current Vivoryon Therapeutics Nv share price?
The current share price of Vivoryon Therapeutics Nv is 4.71 €
What is the 1 year trading range for Vivoryon Therapeutics Nv share price?
Vivoryon Therapeutics Nv has traded in the range of 4.71 € to 4.71 € during the past year
What is the reporting currency for Vivoryon Therapeutics Nv?
Vivoryon Therapeutics Nv reports financial results in EUR
What is the latest annual turnover for Vivoryon Therapeutics Nv?
The latest annual turnover of Vivoryon Therapeutics Nv is EUR -3.62M
What is the latest annual profit for Vivoryon Therapeutics Nv?
The latest annual profit of Vivoryon Therapeutics Nv is EUR -28.34M
What is the registered address of Vivoryon Therapeutics Nv?
The registered address for Vivoryon Therapeutics Nv is WEINBERGWEG 22, HALLE, 06120
What is the Vivoryon Therapeutics Nv website address?
The website address for Vivoryon Therapeutics Nv is www.vivoryon.com
Which industry sector does Vivoryon Therapeutics Nv operate in?
Vivoryon Therapeutics Nv operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BLUBlue Star Capital Plc
8.25p
(230.00%)
2.73M
RCGHRc365 Holding Plc
3.25p
(54.76%)
8.11M
BTCVinanz Limited
22.50p
(34.33%)
872.26k
BANKFiinu Plc
0.65p
(30.00%)
2.26M
TM1Technology Minerals Plc
0.145p
(20.83%)
26.39M
NFXNuformix Plc
0.045p
(-25.00%)
157.31M
EYEEagle Eye Solutions Group Plc
362.00p
(-23.14%)
173.99k
GFINGfinity Plc
0.0625p
(-16.67%)
56.22M
JWNGJaywing Plc
0.525p
(-16.00%)
728.76k
SYMESupply@me Capital Plc
0.003p
(-14.29%)
133.24M
TRPTower Resources Plc
0.0355p
(-10.13%)
1.96B
ORCPOracle Power Plc
0.018p
(-5.26%)
300.79M
LLOYLloyds Banking Group Plc
53.28p
(0.76%)
193.8M
DGIDg Innovate Plc
0.0185p
(-7.50%)
171.19M
NFXNuformix Plc
0.045p
(-25.00%)
157.31M

Discussion

View Full Feed
firebag1 firebag1 4 minutes ago
SANA$$$$ big time Mojocash!!!!how the heck are ya? Been awhile!! Hope you been making money! I took a few year hiatus lol got it going again!
SANA
Structural_Biologist Structural_Biologist 4 minutes ago
I envy your position here. Certainly excited to be able to invest much more heavily once I get a real job and wrap up this Postdoc haha.

But I too am unfazed 🫡
IOVA
marthambles marthambles 5 minutes ago
https://x.com/a_may_md/status/1878918432827293808?s=46
pitcook pitcook 6 minutes ago
P-pe said “ and in fact LWLG won the ECOC Optical Integration award back to back years in 2023 and 2024 ”

WOW O WOW we won a MAJOR AWARD!!!!!! A lamp shaped like a leg would be more valuable. At least it would light up a room. I remember how we were told by Mr. copy and paste that th
LWLG
fuagf fuagf 6 minutes ago
Season 2 The Night Agent arriving Jan 23. Just watched Season 1 a 2nd time, lol, only
recalled a few scenes before they arrived again. Had correct hunches about a couple
of mains, sadness and good gotcha, two extreme feelings on that score.

https://www.google.com/s
KILLAZILLA KILLAZILLA 6 minutes ago
THIS POS SCAM RUN BY LYING GRIFTERS HAVE ZERO PATENTS FOR ANYTHING IN ANY FIELD!!!

DESPERATE PUMPER POSTING LIES IS PATHETIC!!!!
XERI
richme richme 6 minutes ago
Does that mean you flipped on the rest??
MONI
luvwetscent luvwetscent 6 minutes ago
and I thought my crow references were getting old...you're right about the Dipster
ELTP
sylvia07 sylvia07 6 minutes ago
DBMM_A "T-trade" for OTC stocks means a trade executed on the Over-the-Counter (OTC) market, where securities are bought and sold directly between two parties, without the involvement of a centralized exchange like the New York Stock Exchange (NYSE) or Nasdaq; essentially, it's a stock trade happeni
DBMM
Structural_Biologist Structural_Biologist 6 minutes ago
Well said GMH I had similar takeaways.
IOVA
JERSEYHAWG JERSEYHAWG 7 minutes ago
Phew.

Good thing only 11 more months..


Hey cheese

😅
LEHNQ
firebag1 firebag1 7 minutes ago
They will. When they’re ready to unleash the FOMO!
CGAC
wxdog wxdog 7 minutes ago
Begs the question……

What if he’s right…and you aren’t ?

https://finance.yahoo.com/news/mexus-gold-us-signed-non-181500145.html
marcis marcis 7 minutes ago
He’s a clown and doesn’t even trade

He is most probably a paid shrill

Notice the crow was silent today
RDAR
firebag1 firebag1 8 minutes ago
Tough arm chair critics!!
CGAC
Moonboy1 Moonboy1 8 minutes ago
Down more than 75% from its high in a week. Crazy.
RGTI
tw0122 tw0122 8 minutes ago
Insider buying $2.72 buy 5 insiders reported at 434pm low floater 

style="color: rgba(0, 0
IBIO
Huggy Bear Huggy Bear 8 minutes ago
That's ridiculous. There are thousands of legitimate investments out there. But highly promoted garbage like this and other traps are obviously not among them.
HMBL
Cornerstone_Marketing Cornerstone_Marketing 8 minutes ago
Love buying while the bashers are crying! 
I keep adding on lows and will do so until the next 100-300% pop
SPZI
johnnytrader33 johnnytrader33 8 minutes ago
Fraudsters will fraud!!
TSOI
trader59 trader59 9 minutes ago
Geez... this company is going to keep checking boxes on the pump and dump playbook until they run out of them. What's next, gold mining? Blockchain? A cure for cancer?
RONN
capgain capgain 9 minutes ago
Nice one there!
thecryptomarket thecryptomarket 9 minutes ago
CHARTS DON'T LIE ;)
WPFH
iateclube iateclube 9 minutes ago
This is a test
LQMT
facts_matter14 facts_matter14 9 minutes ago
So now the future is the past. How did the future prediction hold up??

“No the future is 21, 22, 23, 24”







.
SRMX

Your Recent History

LSE
0R3M
Vivoryon Therapeutics Nv
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads